therapeutics and clinical risk management

4004 results for therapeutics and clinical risk management

  • vLex Rating
  • Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 Presenter Profiles.

    ...Further key projects in clinical development comprise the three orally ...Company: Altea Therapeutics Corporation Investor Relations Contact: Steven P. ... and fentanyl patches for the rapid management of moderate to severe pain; and (ii) patches for ... of patients who experience, or are at risk of, life threatening episodes of liver failure. ...

  • Big Data and Pharmacovigilance: Using Health Information Exchanges to Revolutionize Drug Safety

    Data on individual patients collected through state and federal health information exchanges has the potential to usher in a new era of drug regulation. These exchanges, produced by recent health care reform legislation, will amass an unprecedented amount of clinical information on drug usage, demographic variables, and patient outcomes. This information could aid the Food and Drug Administration

  • THE VALLEY 200: The most influential leaders in the Valley Area1 2017.

    ... of employee claims prevention via management training and clearly established company ... issues, including environmental and diverse risk assessment matters. She is also a member of the ...She has a doctorate in clinical psychology with an emphasis in organizational ...-ups, Cure Pharmaceutical and Oak Therapeutics, and the non-profit Start-UpKids. He holds a ...

  • BioPartnering Europe 2005 Exhibitor Profiles.

    ... of cancer and plans to initiate clinical trials in 2006. Ambit has raised a total of $51 ...Company: Arrow Therapeutics Ltd Booth/Stand: Open House Presenter: Group 4, ...: trial design and strategy, site management, project management, monitoring, ... discovery and development process, managing risk efficiently, thereby reducing the time and cost ...

  • MASS Opportunities: A Biotechnology Investment Conference Presenter Profiles.

    ... product candidates for which it has clinical data are designed to address unmet clinical needs ... that is developing enhanced natural therapeutics for health maintenance, and the treatment of ... and a novel vaccine for cholesterol management. AVANT has assembled technologies that enable the ... for colorectal cancer in the average-risk population. Colorectal cancer, which is the most ...

  • The Road To IPO: Legal And Regulatory Insights Into Going Public

    ..., which provides on-demand project management software for the commercial construction ... bluebird bio, a clinical-stage biotechnology company developing gene ... PTC Therapeutics, a biopharmaceutical company focused on the ... without significant revenue in high-risk industries, such as life sciences. Although not ...

  • Key Challenges and Issues Facing the Dermatological Therapeutics Markets.

    ...CAPSAICIN . TOPICAL MEDICATIONS IN CLINICAL TRIALS . MOISTURIZERS AND SCALE REMOVERS . TABLE 48 DRUG ...EMERGING DRUGS FOR ICHTHYOSIS . PROGRESS IN THE MANAGEMENT OF ACNE . PLASMA SKIN REGENERATION TECHNOLOGY . TABLE 49 NEW ...MANUFACTURERS OF TNF-BLOCKER DRUGS ORDERED TO HIGHLIGHT RISK OF FUNGAL INFECTIONS . HIGHER CO-PAYS FOR BIOLOGICS IMPACTS ...

  • Biotech In Europe Investor Forum 2003 Exhibitor Profiles.

    ... company focused on the discovery, pre-clinical and early clinical development of new drug ... and production of virus-based therapeutics and vaccines. To date the company has grown to 33 ... sales as drugs, decreasing the development risk. The company operates on a business model that is ... and reverse nitrogen loss, which management believes will translate into a substantial market ...

  • Clinilabs Appoints Senior Medical Director of Clinical Pharmacology Unit (CPU).

    ... and currently serves on the editorial boards of Therapeutics and Clinical Risk Management and the Journal of Clinical ...

  • 2015 NCBiotech company directory.

    ... parenteral drug manufacturing for both clinical and commercial markets. . www.aaipharma.com . AbD ...Their portfolio Includes therapeutics In oncology, cardiology, neurology, nephrology, rology, psychiatry, diabetes and pain management. The North Carolina location is a sales office. . ... microblome to Identify products that reduce risk and improve yields. . www.agbiome.com . Agile ...

  • C21 BioVentures Conference Exhibitor Profiles.

    ... partnered several lead drugs for final clinical testing, marketing and sales. Company: Amphora ... and development of innovative therapeutics. Amphora has created an exceptional pipeline of ... development timelines and reduces risk in bringing cell therapies from bench to a ... testing, a breakthrough in patient management, is a clinically validated, non-invasive method ...

  • ROTH New York Conference 2006 Presenter Profiles.

    ...ArQule's lead clinical-stage programs are based on its Activated ..., a novel vaccine for cholesterol management, and a treatment to reduce complement-mediated ...Company: Cardium Therapeutics Ticker Symbol & Exchange: OTC BB: CDTP Investor ... tools and information for immediate risk assessment and therapeutic monitoring of heart ...

  • Antitrust and the future of nursing: federal competition policy and the scope of practice.

    ... suggesting special patient harms or risks associated with APRN prescribing. (178) . No ... and after surgery--order tests and therapeutics, and prescribe medication, only under a formal ... and delivery or in post-surgical pain management. (209) Two Missouri hospitals testified to their ...Physicians receive far more education, clinical training, and continuing medical education to ...

  • Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use

    The Food and Drug Administration (FDA) is amending the regulations applicable to blood and blood components, including Source Plasma, to make the donor eligibility and testing requirements more consistent with current practices in the blood industry, to more closely align the regulations with current FDA recommendations, and to provide flexibility to accommodate advancing technology. In order to...

    ... structure and (2) for which there may be a risk of transmission by blood or blood components, or ... under the same license or under common management, final Sec. 606.160(e) requires establishments ... for healthcare workers that includes clinical training, currently licensed or certified as a ...'s Blood Centers and Plasma Protein Therapeutics Association, FDA held a workshop entitled ...

  • SEBIO 2003 Exhibitor Profiles.

    ... Services offers a full range of clinical and non-clinical development solutions to ... well-known, branded medicines in pain management, gastroenterology and critical care. The ...Company: Hemocellular Therapeutics, Inc. Media and Investor Relations Contact: E. S. ... Associates provides insurance brokerage, risk management and employee benefit services to ...

  • Medical or recreational marijuana and drugged driving.

    ... between BAC level and impairment or crash risk and that a person's B AC level changes slowly ..., Cannabis Effects on Driving Skills, 59 Clinical Chemistry 478, 479 (2013) ("Cannabis smokers ...See Alliance for Cannabis Therapeutics v. DEA, 930 F.2d 936, 937 n.1 (D.C. Cir. 1991). ...Barnett, et al., Contingency Management for Alcohol Use Reduction: A Pilot Study Using a ...

  • Tobacco Product Standard for Nicotine Level of Combusted Cigarettes

    The Food and Drug Administration (FDA) is issuing this advance notice of proposed rulemaking (ANPRM) to obtain information for consideration in developing a tobacco product standard to set the maximum nicotine level for cigarettes. Because tobacco-related harms ultimately result from addiction to the nicotine in such products, causing repeated use and exposure to toxicants, FDA is considering...

    ... written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, ... content per cigarette that minimizes the risk of central nervous system effects contributing to ... Conditions,'' Human Psychopharmacology-Clinical and Experimental, 10(2):127-136, 1995. 96. ... of Pharmacology and Experimental Therapeutics, 288(3):905-911, 1999. 102. Dwoskin, L.P., L.H. ...

  • BioMed Expo 2004 Exhibitor Profiles.

    ... development of new diagnostics and therapeutics. Our inventory consists of over 45,000 fresh ...BioSolutions is a highly specialized risk management program designed for the Life Sciences ... growth of pharmaceutical, biotechnology, clinical and other related industries in Michigan. Eastern ...

  • SEBIO 2005 Exhibitor Profiles.

    ... being evaluated in the pivotal Phase III clinical trial called ARISE, as an oral therapy for the ... companies to strategic real estate, management talent, manufacturing partners and healthcare ... Innovations, Intrexon, Ocucure Therapeutics, and Surgicaltools.com. Company: GE Healthcare ... a specialty medical company focused on high risk pregnancy care (maternal-fetal medicine). Its ...

  • CED Venture 05 Exhibitor and Sponsor Profiles.

    ...'s most trusted provider of Storage Management Services. The company's comprehensive portfolio ... is a global provider of applied clinical pharmacogenomics services and diagnostic product ... while decreasing associated expenses, risks, and development timelines. Integrated with the ...Company: Oriel Therapeutics Public Relations Contact: Amy Barefoot, ...

  • Companies.

    ...-dose manufacturing facility provides clinical and commercial supplies on contract. . ...(RTP) develops cancer therapeutics. Its lead product under development is ... technologies in the areas of pain management and oncology supportive care. . www.bdsi.com . ...(RTP) develops products that reduce the risk of injury or death from counterfeit drugs. . ...

  • SPECIALISED THERAPEUTICS PARTNERS W/ GENOMIC HEALTH.

    ... a patient's likely benefit from chemotherapy and the overall risk of breast cancer recurrence. This technology has been shown to ... logistics in Australia, including tissue sample management. . Announcing the distribution agreement with Genomic Health, STA ... Genomic Health, Oncotype DX has been evaluated in 15 clinical studies in more than 6,000 patients. These studies include a ...

  • Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results

    - Continued to Execute on "Alnylam 5x15(TM)" Product Strategy with Positive Clinical Data in Multiple RNAi Therapeutic Programs Including ALN-TTR02 for Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR) and ALN-PCS for Treatment of Hypercholesterolemia - - Advanced Proprietary Conjugate Delivery Platform Enabling Subcutaneous Delivery of RNAi Therapeutics Towards the Clinic,...

    ...(Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated ..."2012 was a remarkable year of clinical achievement for Alnylam and for the advancement ... Advisory Board and Developed Management Team. Alnylam elected Daniel J. Rader, M.D. to ... unexpected expenditures, as well as those risks more fully discussed in the "Risk Factors" filed ...

  • 16th Annual Wall Street Analyst Forum Presenting Company Profiles.

    ... performs development, acquisition, management, leasing and brokerage services for its portfolio ... growth hormone and cromolyn sodium into clinical trials. Emisphere has strategic alliances with ... prescription and over-the-counter therapeutics. The Company's proprietary technology uses a ...The Company has also lowered its portfolio risk on the downside with fixed price royalties and ...

  • The Road To IPO: Legal And Regulatory Insights Into Going Public (April 2014)

    ... Aquinox Pharmaceuticals, a clinical-stage pharmaceutical company discovering and ... company developing non-opioid therapeutics for the treatment of pain, initially in the ... provider of payroll and human capital management software solutions for medium-sized ... Semler Scientific, an emerging medical risk-assessment company with a product allowing ...